S-Ray is at a pre-IPO stage. This is your opportunity to invest.
Our 9 years of work developing low-cost, highly accurate, full-arch intraoral 3D scanning equipment is rapidly approaching FDA clearance followed by a potential IPO.
Due to a recent discovery our FDA clearance has been expedited and as a result, this 506(c) capital investment offering will close upon receipt of clearance to sell our intraoral scanner. We anticipate this occurring as early as August of 2017.
Our business model will allow us to capture revenue four different ways:
- Capital sales
- Disposable (single use) sales
- Content delivery
We are only offering 1.5 million shares of stock and will not over-subscribe this offering. Therefore, this offering is only available until it is full, or until we receive clearance – whichever comes first.
Forward-Looking Statements: This website contains “forward-looking statements,” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future events, trends, contingencies or results, appear at various places in this website and use words like “anticipate,” “assume,” “believe,” “continue,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “potential,” “predict,” “project,” “strategy,” “target” and similar terms, and future or conditional tense verbs like “could,” “may,” “might,” “should,” “will” and “would.” For example, management may use forward-looking statements when addressing topics such as: the outcome of contingencies; future actions by regulators; changes in the Company’s business strategies and methods of generating revenue; the development and performance of the Company’s services and products; the expected impact of acquisitions and dispositions; the Company’s effective tax rates; and the Company’s cost structure, dividend policy, cash flows or liquidity.